CXCL5 and neoplasm: Kim et al. using a mathematical model were able to predict a decrease in the growth rate of residual glioma cells exposed to therapeutic agents targeting CXCL5, a member of the CXC subfamily of chemokines with an important function in tumour angiogenesis [8].